Data Sheet 1_Population pharmacokinetic model for meropenem in pediatric patients: a systematic review.pdf

Pediatric patients with various characteristics were included, and most had severe infections or were admitted to the ICU. Four studies focused on patients with organ support, mainly renal replacement and extracorporeal membrane oxygenation. The sample sizes were usually small (sample sizes no more than 50).

Fourteen studies ultimately obtained the 2-CMT model, and the remaining studies used the 1-CMT model, except for one 3-CMT model. Body weight, age and renal function indicators were the most common covariates. The typical CL values ranged from 0.50–13.22 L/h or 0.122–0.526 L/h/kg.

The Vcs for the 2-CMT models ranged from 0.969–21.4 L or 0.272–0.57 L/kg. Most models underwent internal validation, but only one study performed external validation.</p>Conclusion<p>This study successfully integrated the current meropenem PPK models for pediatric patients, which would benefit the clinical application of MIPD. Clinicians should select appropriate models on the basis of patient characteristics carefully, and therapeutic drug monitoring is important at the current stage.

External validation and well-designed studies on specific subpopulations, such as patients with organ support, neonates, and specific disease status, are needed.</p>Systematic review registration<p>PROSPERO, identifier (CRD420261481301).</p>